Pharmafile Logo

Perjeta

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Perjeta in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Perjeta.

35

Global Revenue Ranking

Recent articles on PMLiVE featuring Perjeta

- PMLiVE
ESMO 2025 – ensuring innovation isn’t lost in translation

This year marks the congress’s 50th anniversary, with the theme: Many journeys. One global community

- PMLiVE
Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

- PMLiVE
Roche’s Perjeta-based breast cancer regimen shows sustained survival benefits

Approximately 56,800 new breast cancer cases are diagnosed in the UK every year

- PMLiVE
Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11

The reference medicine holds approvals for multiple HER2-positive breast cancer indications

Roche Basel Switzerland
Roche gets EU approval for fixed-dose Herceptin/Perjeta combination

Treatment can be administered as an injection instead of an intravenous infusion

- PMLiVE
EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

Antibody drug conjugate gained approval in US in December

- PMLiVE
Cortellis Drugs to Watch in 2020 report

The latest Cortellis Drugs to Watch report highlights medicines that treat high prevalence conditions

- PMLiVE
Seattle Genetics wins FDA priority review for oral HER2 drug

If approved will compete with AZ/Daiichi Sankyo’s Enhertu

- PMLiVE
20 for 2020 – Five pharma companies to watch

As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020

- PMLiVE
Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

- PMLiVE
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

Early approval comes well ahead of schedule

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links